Journal of perinatology : official journal of the California Perinatal Association · 2026
Universal practice based management of patent ductus arteriosus in premature neonates in 2025: BRONX PDA protocol and BRONX clinical scoring system (BCSS).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lisboa Priscila, Gada Jinal, Gaudig Antonia, Sivakumar Adithya, Rastogi Shantanu, Kwon Elena N, Fazzari Melissa, Sutton Nicole, Gupta Manoj
Аннотация
BACKGROUND: Management of hemodynamically significant patent ductus arteriosus (hsPDA) in neonates remains controversial, with wide variation in practice among neonatologists and pediatric cardiologists.
METHODS: An IRB-approved anonymous 12-item survey assessing hsPDA screening, treatment preferences, and perceived risks and benefits was distributed to over 5,000 U.S. providers. Responses were statistically analyzed using standard parameters.
RESULTS: A total of 462 completed surveys were analyzed (35% cardiologists, 64% neonatologists). Most providers-initiated PDA screening based on clinical condition. Medical therapy was the preferred first-line treatment. Nearly one-third favored conservative management when echocardiographic hsPDA was present with minimal clinical concern, while others delayed intervention beyond the neonatal period. Pediatric cardiologists were more likely than neonatologists to believe PDA closure reduces morbidity and mortality, although most providers still elected to treat hsPDA. Neonatologists favored medical and percutaneous approaches over surgery.
CONCLUSION: Significant inter-specialty variation persists in hsPDA management, highlighting the need for standardized, clinically integrated approaches.
METHODS: An IRB-approved anonymous 12-item survey assessing hsPDA screening, treatment preferences, and perceived risks and benefits was distributed to over 5,000 U.S. providers. Responses were statistically analyzed using standard parameters.
RESULTS: A total of 462 completed surveys were analyzed (35% cardiologists, 64% neonatologists). Most providers-initiated PDA screening based on clinical condition. Medical therapy was the preferred first-line treatment. Nearly one-third favored conservative management when echocardiographic hsPDA was present with minimal clinical concern, while others delayed intervention beyond the neonatal period. Pediatric cardiologists were more likely than neonatologists to believe PDA closure reduces morbidity and mortality, although most providers still elected to treat hsPDA. Neonatologists favored medical and percutaneous approaches over surgery.
CONCLUSION: Significant inter-specialty variation persists in hsPDA management, highlighting the need for standardized, clinically integrated approaches.